Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Category: #health  By Pankaj Singh  Date: 2019-11-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results achieved  after substituting from CT-P13 IV with CT-P13 SC, in people with RA (rheumatoid arthritis). The data was put forward at the American College of Rheumatology (ACR) annual meeting.

A previous study compared the pharmacokinetics, efficacy & and safety profiles of both CT-P13 IV and CT-P13 SC in people with rheumatoid arthritis over 30 weeks. This study demonstrated the non-inferiority of CT-P13 SC as compared to CT-P13 IV.

Rene Westhovens, Professor of Rheumatology, University Hospitals KU Leuven, Belgium, was reportedly quoted saying that non-inferiority for CT-P13 SC to CT-P13 IV was supported by the change from baseline CRP (DAS28) at Week 22. Up to Week 54, serum concentration of CT-P13 SC was well retained. Over the study period, safety outcomes of CT-P13 SC exhibited comparable profiles to CT-P13 IV.

Westhovens added that CT-P13 SC indicated lower ADA than CT-P13 IV, which implies high trough level possibly leading to better PK pattern, as well as, positive efficacy profile. The findings show that the new SC formulation of CT-P13 through pre-filled syringe could provide advantageous benefits to people with an alternative convenient way of administration.

 Hyoung-Ki Kim, V.C., Celltrion Healthcare, stated that with CT-P13 SC at the disposal, patients can now be treated utilizing infliximab SC before switching over to other costly antibodies with a different mechanism of action such as JAK-inhibitors. For the second-line treatment of rheumatoid arthritis, Celltrion Healthcare is looking forward to target CT-P13 SC as the desired agent. With the medical formulation of CT-P13 and the development of the biosimilar adalimumab, CT-P17, has immense potential in improving access to treatment as well as expanding treatment options worldwide.

Hyoung-Ki Kim further added that the pharmaceutical company remains highly committed to developing biosimilar portfolio in order to deliver value to patients and healthcare providers.
 

Source Credit: https://finance.yahoo.com/news/data-show-non-inferiority-efficacy-213000945.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...

U.S. government could issue new rules to block shipments to Huawei
U.S. government could issue new rules to block shipments to Huawei
By Pankaj Singh

  Trump administration had issued 75 licenses to allow Huawei suppliers to resume sales U.S. Commerce Department and other authorities focused on utilizing De minimis Rule The U.S. government is reportedly considering new policies to restr...

Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
By Pankaj Singh

Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed de...